Abstract
Background
Both Strontium Ranelate (SR) and Calcitonin (CT) can be used to treat osteoporosis. Calcitonin was actually one of the very initial medicines used to treat osteoporosis, especially in postmenopausal cases. However, the fracture prevention effect of Calcitonin is only proven to be in vertebrae and that too with nasal route only. When comparing Calcitonin with other conventional medications in treating osteoporosis, Calcitonin has got no additional advantages. Strontium Ranelate has got double effect, i.e., less bone resorption and more bone formation. Therefore, it can lead to an increase in bone mass significantly. Strontium Ranelate has been proven to decrease the risk of non-vertebral fractures as well as vertebral fractures.
Conclusion
Both Calcitonin and Strontium Ranelate are used only as a second-line therapy for the treatment of osteoporosis and not as first-line therapy, mainly because of their safety concern and also because they do not provide any advantages compared to other therapy for the treatment of osteoporosis.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
SR widely available in indian markets especially the online pharmaceutical stores. No other significant data for the statement available.
References
Chesnutt, C. H., 3rd., Azria, M., Silverman, S., et al. (2008). Salmon calcitonin: a review of current and future therapeutic indications. Osteoporosis International., 19(4), 479–491.
Szucs, J., Horvath, C., Kollin, E., et al. (1992). Three-year calcitonin combination therapy for postmenopausal osteoporosis with crush fractures of the spine. Calcified Tissue International, 50(1), 7–10.
Altman, R. D., & Collins-Yudiskas, B. (1987). Synthetic human calcitonin in refractory Paget’s disease of bone. Archives of Internal Medicine, 147(7), 1305–1308.
Quatraro, A., Minei, A., De Rosa, N., et al. (1992). Calcitonin in painful diabetic neuropathy. Lancet, 339(8795), 746–747.
Lyritis, G. P., Paspati, I., Karachalios, T., et al. (1997). Pain relief from nasal salmon calcitonin in osteoporotic vertebral crush fractures. A double-blind, placebo-controlled clinical study. Acta Orthopaedica Scandinavica, 275, 112–114.
Ozsoy, Y., Gungor, S., & Cevher, E. (2009). Nasal delivery of high molecular weight drugs. Molecules, 14(9), 3754–3779.
Henriksen, K., Byrjalsen, I., Andersen, J. R., et al. (2016). A randomized, double-blind, multicenter, placebo-controlled study to evaluate the efficacy and safety of oral salmon calcitonin in the treatment of osteoporosis in postmenopausal women taking calcium and vitamin D. Bone, 91, 122–129.
Wells, G., Chernoff, J., Gilligan, J. P., et al. (2016). Does salmon calcitonin cause cancer? A review and meta-analysis. Osteoporosis International., 27, 13–19.
Sun, L. M., Lin, M. C., Muo, C. H., et al. (2014). Calcitonin nasal spray and increased cancer risk: A population-based nested case-control study. Journal of Clinical Endocrinology and Metabolism, 99(11), 4259–4264.
Meunier, P. J., Roux, C., Seeman, E., Ortolani, S., Badurski, J. E., et al. (2004). The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. New England Journal of Medicine, 350, 459–468.
Reginster, J. Y., Seeman, E., De Vernejoul, M. C., Adami, S., Compston, J., et al. (2005). Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis, Treatment of Peripheral Osteoporosis (TROPOS) study. Journal of Clinical Endocrinology and Metabolism, 90, 2816–2822.
Reginster, J. Y., Bruyère, O., Sawicki, A., Roces-Varela, A., Fardellone, P., et al. (2009). Long-term treatment of postmenopausal osteoporosis with strontium ranelate: Results at 8 years. Bone, 45, 1059–1064.
Rizzoli, R., Chapurlat, R. D., Laroche, J. M., Krieg, M. A., Thomas, T., et al. (2012). Effects of strontium ranelate and alendronate on bone microstructure in women with osteoporosis. Results of a 2-year study. Osteoporosis International., 23, 305–315.
Chavassieux, P., Meunier, P. J., Roux, J. P., Portero-Muzy, N., Pierre, M., et al. (2014). Bone histomorphometry of transiliac paired bone biopsies after 6 or 12 months of treatment with oral strontium ranelate in 387 osteoporotic women: A randomized comparison to alendronate. Journal of Bone and Mineral Research, 29, 618–628.
Ammann, P., & Rizzoli, R. (2013). Strontium ranelate treatment improves bone material level properties in human transiliac bone biopsy specimens. Osteoporosis International, 24, S43.
Jobke, B., Burghardt, A. J., Muche, B., Hahn, M., Semler, J., et al. (2011). Trabecular reorganization in consecutive iliac crest biopsies when switching from bisphosphonate to strontium ranelate treatment. PLoS ONE, 6, e23638.
European Medicines Agency. Assessment report—periodic safety update report (EPAR—Protelos-H-C-560-PSU31).
Cooper, C., Fox, K. M., & Borer, J. S. (2014). Ischaemic cardiac events and use of strontium ranelate in postmenopausal osteoporosis: A nested case-control study in the CPRD. Osteoporosis International, 25, 737–745.
Abrahamsen, B., Grove, E. L., & Vestergaard, P. (2014). Nationwide registry- based analysis of cardiovascular risk factors and adverse outcomes in patients treated with strontium ranelate. Osteoporosis International, 25, 757–762.
Svanström, H., Pasternak, B., & Hviid, A. (2014). Use of strontium ranelate and risk of acute coronary syndrome: Cohort study. Annals of the Rheumatic Diseases, 73, 1037–1043.
Funding
Nil.
Author information
Authors and Affiliations
Contributions
AG: concepts, design, definition of intellectual content, literature search, clinical studies, experimental studies, data acquisition, data analysis, statistical analysis, manuscript preparation, manuscript editing, manuscript review, and guarantor. SA: concepts, design, definition of intellectual content, literature search, clinical studies, experimental studies, data acquisition, data analysis, statistical analysis, manuscript preparation, manuscript editing, manuscript review, and guarantor.
Corresponding author
Ethics declarations
Conflict of Interest
Dr. Abdul Ghani and Dr. Sakib Arfee declare that they have no conflict of interest.
Ethical Standard
This article does not contain any studies with human or animal subjects performed by the any of the authors.
Informed Consent
For this type of study, informed consent is not required.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Ghani, A., Arfee, S. Role of Calcitonin and Strontium Ranelate in Osteoporosis. JOIO 57 (Suppl 1), 115–119 (2023). https://doi.org/10.1007/s43465-023-01034-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s43465-023-01034-x